Wells Fargo Abbott notes (Abt) and Dexcom (DXCM) revealed that on December 20, they reached a settlement and entered into a cross-licensing agreement to resolve all pending patent litigation in the United States and Europe for a period of 10 years. Under the agreement, the two companies granted each other a royalty-free, non-exclusive, fully paid, worldwide license to certain patents and patent applications related to analytics sensing, including all patents asserted in the lawsuit. The company expected that the two parties would eventually reach a settlement, so this announcement does not come as a complete surprise.
First published on The fly – The ultimate source for breaking financial news that moves the market in real time. Try now >>
See Hot Stocks for Insiders on TipRanks >>
Read more about DXCM: